Analysis and optimisation of SPL products using goal models.

https://conf.researchr.org/details/RE-2023/RE-2023-Research-Papers/10/Analysis-and-optimisation-of-SPL-products-using-goal-modelsThe Internet of Things is one of the core drivers of variability modelling and requires explicit mechanisms to manage it. A key technology for addressing this variability is product line engineering. This approach uses a reference architecture to establish a well-designed set of assets that fit together, the Software Product Line (SPL). One of the limitations of variability models is they do not provide information about the quality of new products or how they achieve stakeholder requirements. Several approaches tackle this issue by integrating variability models with goal models. The main challenge is conciliating the different variability perspectives to make the joint use of both models possible without the loss of information or alterations to the models’ semantics. In this work, we present a framework for analysing and optimising SPL products considering stakeholders’ requirements that respects the semantics of both models. The framework is based on Integer Linear Programming (ILP), a field of mathematical programming. Variability and goal models are formalised as a set of linear constraints and are linked using mapping functions. As a proof of concept, we present a tool that takes both models and mapping functions to generate an ILP problem that can be solved using Matlab.This work is supported by the projects IRIS PID2021-12281 2OB-I00 (co-financed by FEDER funds) and by DISCO B1- 201212 funded by Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

Role of age and comorbidities in mortality of patients with infective endocarditis

[Purpose]: The aim of this study was to analyse the characteristics of patients with IE in three groups of age and to assess the ability of age and the Charlson Comorbidity Index (CCI) to predict mortality. [Methods]: Prospective cohort study of all patients with IE included in the GAMES Spanish database between 2008 and 2015.Patients were stratified into three age groups:<65 years,65 to 80 years,and ≥ 80 years.The area under the receiver-operating characteristic (AUROC) curve was calculated to quantify the diagnostic accuracy of the CCI to predict mortality risk. [Results]: A total of 3120 patients with IE (1327 < 65 years;1291 65-80 years;502 ≥ 80 years) were enrolled.Fever and heart failure were the most common presentations of IE, with no differences among age groups.Patients ≥80 years who underwent surgery were significantly lower compared with other age groups (14.3%,65 years; 20.5%,65-79 years; 31.3%,≥80 years). In-hospital mortality was lower in the <65-year group (20.3%,<65 years;30.1%,65-79 years;34.7%,≥80 years;p < 0.001) as well as 1-year mortality (3.2%, <65 years; 5.5%, 65-80 years;7.6%,≥80 years; p = 0.003).Independent predictors of mortality were age ≥ 80 years (hazard ratio [HR]:2.78;95% confidence interval [CI]:2.32–3.34), CCI ≥ 3 (HR:1.62; 95% CI:1.39–1.88),and non-performed surgery (HR:1.64;95% CI:11.16–1.58).When the three age groups were compared,the AUROC curve for CCI was significantly larger for patients aged <65 years(p < 0.001) for both in-hospital and 1-year mortality. [Conclusion]: There were no differences in the clinical presentation of IE between the groups. Age ≥ 80 years, high comorbidity (measured by CCI),and non-performance of surgery were independent predictors of mortality in patients with IE.CCI could help to identify those patients with IE and surgical indication who present a lower risk of in-hospital and 1-year mortality after surgery, especially in the <65-year group

HADES: An NFV solution for energy-efficient placement and resource allocation in heterogeneous infrastructures

&lt;p&gt;Network Function Virtualization (NFV) aims to replace traditional network functions running in proprietary hardware with software instances (i.e., Virtual Network Functions, VNFs) embedded in general-purpose virtualization solutions. Aware that the transition to a fully virtualized network infrastructure will pay a high energy cost, especially in IoT systems composed of a myriad of devices, energy efficiency is one of the key innovative targets of future networks. Edge computing should be considered in IoT environments to save time and energy by processing data near the producer devices. However, applying NFV in the context of IoT/Edge/Cloud environments complicates the placement of VNFs, due to the inherent heterogeneous nature of such environments and the variety of resource demands. This paper proposes an energy-aware placement of service function chains of VNFs and a resource-allocation solution for heterogeneous edge infrastructures that considers the computation and communication delays according to the VNFs' location in the infrastructure.&lt;/p&gt;&lt;p&gt;The solution has been integrated with the ETSI-sponsored project Open Source Management and Orchestration (OSM) as an extension called HADES, which allows the configuration of VNFs and their subsequent resource allocation and deployment at the edge, minimizing energy consumption and ensuring a quality of service. We have applied the deployment of augmented reality services in real and simulated scenarios. The results show up to a 59% reduction in power consumption and QoS compliance in all scenarios considered compared to default OSM placement and four other allocation policies. We prove that our solution has negligible power overhead, and validate the scalability and applicability of HADES.&lt;/p&gt;&lt;p&gt;This work is supported by the European Union's H2020 research and innovation programme under grant agreement DAEMON 101017109 and by the projects co-financed by FEDER funds LEIA, Spain UMA18-FEDERJA-15 and IRIS, Spain PID2021-122812OB-I00 (MCI/AEI).&lt;/p&gt

Role of age and comorbidities in mortality of patients with infective endocarditis.

The aim of this study was to analyse the characteristics of patients with IE in three groups of age and to assess the ability of age and the Charlson Comorbidity Index (CCI) to predict mortality. Prospective cohort study of all patients with IE included in the GAMES Spanish database between 2008 and 2015.Patients were stratified into three age groups: A total of 3120 patients with IE (1327  There were no differences in the clinical presentation of IE between the groups. Age ≥ 80 years, high comorbidity (measured by CCI),and non-performance of surgery were independent predictors of mortality in patients with IE.CCI could help to identify those patients with IE and surgical indication who present a lower risk of in-hospital and 1-year mortality after surgery, especially in th

Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort

Objectives: This study aimed to assess the real use of cefazolin for methicillin-susceptible Staphylococcus aureus (MSSA) infective endocarditis (IE) in the Spanish National Endocarditis Database (GAMES) and to compare it with antistaphylococcal penicillin (ASP). Methods: Prospective cohort study with retrospective analysis of a cohort of MSSA IE treated with cloxacillin and/or cefazolin. Outcomes assessed were relapse; intra-hospital, overall, and endocarditis-related mortality; and adverse events. Risk of renal toxicity with each treatment was evaluated separately. Results: We included 631 IE episodes caused by MSSA treated with cloxacillin and/or cefazolin. Antibiotic treatment was cloxacillin, cefazolin, or both in 537 (85%), 57 (9%), and 37 (6%) episodes, respectively. Patients treated with cefazolin had significantly higher rates of comorbidities (median Charlson Index 7, P <0.01) and previous renal failure (57.9%, P <0.01). Patients treated with cloxacillin presented higher rates of septic shock (25%, P = 0.033) and new-onset or worsening renal failure (47.3%, P = 0.024) with significantly higher rates of in-hospital mortality (38.5%, P = 0.017). One-year IE-related mortality and rate of relapses were similar between treatment groups. None of the treatments were identified as risk or protective factors. Conclusion: Our results suggest that cefazolin is a valuable option for the treatment of MSSA IE, without differences in 1-year mortality or relapses compared with cloxacillin, and might be considered equally effective